AU752510B2 - Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action - Google Patents

Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action Download PDF

Info

Publication number
AU752510B2
AU752510B2 AU16907/99A AU1690799A AU752510B2 AU 752510 B2 AU752510 B2 AU 752510B2 AU 16907/99 A AU16907/99 A AU 16907/99A AU 1690799 A AU1690799 A AU 1690799A AU 752510 B2 AU752510 B2 AU 752510B2
Authority
AU
Australia
Prior art keywords
compound
defined above
same meanings
pct
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU16907/99A
Other languages
English (en)
Other versions
AU1690799A (en
Inventor
Harukazu Fukami
Norio Inomata
Tomoe Kamei
Akira Mizuno
Makoto Shibata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asubio Pharma Co Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Publication of AU1690799A publication Critical patent/AU1690799A/en
Application granted granted Critical
Publication of AU752510B2 publication Critical patent/AU752510B2/en
Assigned to DAIICHI SUNTORY PHARMA CO., LTD reassignment DAIICHI SUNTORY PHARMA CO., LTD Alteration of Name(s) in Register under S187 Assignors: SUNTORY LIMITED
Assigned to DAIICHI ASUBIO PHARMA CO., LTD. reassignment DAIICHI ASUBIO PHARMA CO., LTD. Request to Amend Deed and Register Assignors: DAIICHI SUNTORY PHARMA CO., LTD
Assigned to ASUBIO PHARMA CO., LTD. reassignment ASUBIO PHARMA CO., LTD. Request to Amend Deed and Register Assignors: DAIICHI ASUBIO PHARMA CO., LTD.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU16907/99A 1997-12-26 1998-12-25 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action Ceased AU752510B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9366757A JPH11193290A (ja) 1997-12-26 1997-12-26 ピロールスルホンアミド系化合物
JP09-366757 1997-12-26
PCT/JP1998/005955 WO1999033841A2 (en) 1997-12-26 1998-12-25 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action

Publications (2)

Publication Number Publication Date
AU1690799A AU1690799A (en) 1999-07-19
AU752510B2 true AU752510B2 (en) 2002-09-19

Family

ID=18487596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16907/99A Ceased AU752510B2 (en) 1997-12-26 1998-12-25 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action

Country Status (9)

Country Link
US (3) US6331623B1 (enExample)
EP (1) EP0970089A2 (enExample)
JP (1) JPH11193290A (enExample)
KR (1) KR20000075642A (enExample)
CN (2) CN1131870C (enExample)
AU (1) AU752510B2 (enExample)
CA (1) CA2282815A1 (enExample)
HU (1) HUP0001183A3 (enExample)
WO (1) WO1999033841A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193289A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド誘導体
JPH11193290A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド系化合物
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3976101A4 (en) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3198117B2 (ja) 1990-02-07 2001-08-13 サントリー株式会社 ピロロアゼピン誘導体
FR2675802B1 (fr) * 1991-04-26 1993-12-24 Rhone Poulenc Rorer Sa Antiserotonines, leur preparation et les medicaments les contenant.
ATE236163T1 (de) 1991-08-07 2003-04-15 Suntory Ltd Pyrroloazepinverbindungen
AU655841B2 (en) * 1991-08-07 1995-01-12 Daiichi Suntory Pharma Co., Ltd Pyrroloazepine derivative
ATE246682T1 (de) * 1993-12-24 2003-08-15 Daiichi Suntory Pharma Co Ltd Benzothiazinderivate
DE69630184T2 (de) 1995-11-02 2004-08-12 Daiichi Suntory Pharma Co., Ltd. Verfahren zur Herstellung von 1-substituierten Pyrrol-3-carbonsäure-Derivaten
ES2179218T3 (es) 1995-12-01 2003-01-16 Suntory Ltd Derivados de pirroloacepina.
JPH10251258A (ja) 1997-03-14 1998-09-22 Suntory Ltd ピロロアゼピン系化合物
JPH11193289A (ja) 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド誘導体
JPH11193290A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド系化合物
ES2220396T3 (es) 1999-02-17 2004-12-16 Daiichi Suntory Pharma Co., Ltd. Farmacos terapeuticos para la claudicacion intermitente que comprenden pirroloazepinas.

Also Published As

Publication number Publication date
US20020137928A1 (en) 2002-09-26
JPH11193290A (ja) 1999-07-21
EP0970089A2 (en) 2000-01-12
CN1495163A (zh) 2004-05-12
CA2282815A1 (en) 1999-07-08
CN1131870C (zh) 2003-12-24
US20030229070A1 (en) 2003-12-11
HUP0001183A2 (hu) 2000-10-28
US6583296B2 (en) 2003-06-24
US6331623B1 (en) 2001-12-18
US6743913B2 (en) 2004-06-01
CN1193014C (zh) 2005-03-16
WO1999033841A2 (en) 1999-07-08
AU1690799A (en) 1999-07-19
HUP0001183A3 (en) 2002-12-28
WO1999033841B1 (en) 2001-05-25
CN1261366A (zh) 2000-07-26
WO1999033841A3 (en) 1999-09-02
KR20000075642A (ko) 2000-12-26

Similar Documents

Publication Publication Date Title
KR20080058456A (ko) 비만, 정신 질환 및 신경 질환의 치료를 위한테트라히드로피롤로[3,2-ｃ]피리딘-4-온 유도체의 제조 및용도
US6713634B2 (en) Pyrroloazepine derivatives
EP0557526B1 (en) Pyrroloazepine compound
US6271223B1 (en) Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action
US6294677B1 (en) Thiopyran derivatives
US6743913B2 (en) Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and α-1-blocking action
US6211362B1 (en) Pyrroloazepine compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: DAIICHI SUNTORY PHARMA CO., LTD

Free format text: FORMER OWNER WAS: SUNTORY LIMITED